Children's Hospital Boston | GenomeWeb

Children's Hospital Boston

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.

A Mount Sinai researcher described early results from the clinical trial aimed at evaluating the utility of genomic sequencing in healthy and ill newborns.

Clinicians in Boston are beginning to sequence newborns' genomes, CBS Boston reports.

Clinicians in the hospital will use IBM's Watson to identify possible options for diagnosing and treating rare pediatric diseases starting with kidney disease.

By editing a promoter of an enhancer of the mutated hemoglobin responsible for sickle cell disease, the researchers may have found a way to treat it.

Using Quanterix's Simoa technology, the group developed assays to detect C. diff toxins with a high degree of sensitivity and specificity.

Off and Running

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

Researchers used exome sequencing to pinpoint DOCK2 mutations as causative of early childhood immune deficiency that leads to severe infections. 

The study shows the power of mass spectrometry and informatics to reveal new gene networks and molecular pathways in neurobiology.

The methods could help lead to a tool to predict off-target activity and design highly specific guide RNAs for use in clinical applications of CRISPR/Cas9.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.